Additional file 6: of Aberrant STAT phosphorylation signaling in peripheral blood mononuclear cells from multiple sclerosis patients

Table S5. Comparison of levels of phosphorylated proteins between RRMS and SPMS patients in baseline conditions. Levels of phosphorylated proteins in each cell type in RRMS and SPMS patients. Values represent the mean fluorescence intensity and standard deviation for each group. (DOCX 14 kb

Additional file 7: of Aberrant STAT phosphorylation signaling in peripheral blood mononuclear cells from multiple sclerosis patients

Table S6. Comparison of levels of phosphorylated proteins between RRMS and SPMS patients after in vitro stimulation. Levels of phosphorylated proteins in each cell type in RRMS and SPMS patients. Values represent the mean fluorescence intensity and standard deviation for each group. (DOCX 15 kb

Additional file 2: of Aberrant STAT phosphorylation signaling in peripheral blood mononuclear cells from multiple sclerosis patients

Table S1. Comparison of levels of phosphorylated proteins between MS patients and controls in baseline conditions. Levels of phosphorylated proteins in each cell type in healthy controls and RRMS patients. Values represent the mean fluorescence intensity and standard deviation for each group. (DOCX 14 kb

Additional file 10: of Aberrant STAT phosphorylation signaling in peripheral blood mononuclear cells from multiple sclerosis patients

Table S9. Correlation between STAT phosphorylation and HLA-E, HLA-ABC, and HLA-DR expression in different cell populations. Correlation between levels of p-STAT1, p-STAT3, p-STAT4, p-STAT5, and p-STAT6 proteins and HLA-E, HLA-ABC, and HLA-DR expression after IFN-α or IFN-γ stimulation. Cor: Spearman coefficient; p: p values. Significant correlations are highlighted in bold. (DOCX 15 kb

Additional file 5: of Aberrant STAT phosphorylation signaling in peripheral blood mononuclear cells from multiple sclerosis patients

Table S4. Comparison of levels of p38MAPK, Erk1/2, STAT1, and STAT6 between MS patients and controls. Levels of selected proteins in each cell type in healthy controls and RRMS patients. Values represent the mean fluorescence intensity and standard deviation for each group. (DOCX 13 kb

Comparisons of the phenotype frequencies of the <i>HLA-DRB1</i> alleles.

<p>*^aCompared with HCs, p^corr = 0.0196, OR  = 2.217, 95% CI  = 1.389–3.539.</p><p>*^bCompared with HCs, p^corr = 0.0056, OR  = 3.660, 95% CI  = 1.802–7.431.</p><p>*^cCompared with HCs, p^corr = 0.0084, OR  = 0.279, 95% CI  = 0.135–0.575.</p><p>*^dCompared with HCs, p^corr = 0.0392, OR  = 2.624, 95% CI 1.432–4.809.</p><p>p^uncorr was corrected by multiplying the value by 28 to calculate p^corr.</p><p>CI, confidence interval; CSF, cerebrospinal fluid; HCs, healthy controls; MS, multiple sclerosis; OR, odds ratio; p^corr, corrected p value.</p

Comparisons of the frequencies of antibodies against common infectious agents.

<p>*p = 0.0119, compared with IgG abnormality (−) MS patients.</p><p>**p = 0.0451, compared with HCs.</p><p>***p = 0.0474, compared with HCs.</p><p>*^,**^,***Significant difference between the linked values (p<0.05).</p><p>The age of the patients during examination did not differ significantly among HCs and MS patients, regardless of the presence or absence of IgG abnormality (mean ± SD in years: 37.21±12.54 for MS; 36.19±11.36 for IgG abnormality-positive MS; 39.00±14.39 for IgG abnormality-negative MS; and 38.93±12.11 for HCs).</p><p>CSF, cerebrospinal fluid; EBV, Epstein-Barr virus; HCs, healthy controls; MS, multiple sclerosis; p^corr, corrected p value; VZV, varicella zoster virus.</p

Correlation of cytokine and chemokine levels in patients with RRMS and NMO/NMOSD in the relapse phase.

<p>Among the cytokines and chemokines analyzed, distances of each pair of cytokines/chemokines, based on Spearman's correlation coefficient, of RRMS and NMO/NMOSD in the relapse phase were shown as a heatmap. NMO = neuromyelitis optica; NMOSD = neuromyelitis optica spectrum disorder; RRMS = relapsing remitting multiple sclerosis.</p

Proportions of patients with CSF IgG abnormality by year of birth.

<p>Among the MS patients, the proportion of patients with CSF IgG abnormality did not change significantly with advancing year of birth. CSF, cerebrospinal fluid; MS, multiple sclerosis.</p

Proportions of patients with <i>Helicobacter pylori</i> infection by year of birth.

<p>Among the MS patients, the proportion of patients with <i>H. pylori</i> decreased markedly in those born after 1965. MS, multiple sclerosis.</p